Global bromocriptine trial for postpartum heart failure (PPCM)
Official title: 1/2 GLobal trial Of Bromocriptine for PeriPartum CardioMyopathy (GLOBal PPCM)
Funded at University of Alabama at Birmingham · NIH-11625546 · Data updated 2026-11-12
A large international trial will test whether adding bromocriptine to standard heart failure treatment helps women with peripartum cardiomyopathy after giving birth.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Alabama at Birmingham NIH-funded |
| Lab location | 1 site (Birmingham, United States) |
| Project start | September 15, 2026 |
| Project end | August 31, 2033 |
| Funding year | 2026 |
| Award (this year) | $31,320 |
| NIH project number | 3UG3HL177574-01A1S5 |
| Project ID | NIH-11625546 on NIH RePORTER |
Who could benefit from this research
✓Could help
Postpartum women diagnosed with peripartum cardiomyopathy who are receiving standard heart failure therapy and have recently given birth.
✕Less likely to help
Women with PPCM who cannot take bromocriptine due to contraindications or who experience adverse effects may not benefit.
What this research studies
This study enrolls 650 postpartum PPCM patients across at least 18 sites in 15 LMICs, randomizing them to bromocriptine or placebo in addition to their usual heart failure care. Participants are followed for six months to see if there are improvements in survival, heart function, and hospital readmissions. The trial aims to carefully monitor safety for both mothers and babies, including effects on lactation. If bromocriptine proves beneficial and safe, it could become an important addition to PPCM care on a global scale.
Why it matters
Potential benefit: If successful, the treatment could reduce maternal deaths and improve heart function in women with PPCM.
How similar studies have gone: Preliminary small studies and animal data suggested potential benefits, but a large-scale trial is needed to confirm.
Where this research is happening
-
University of Alabama at Birmingham
Birmingham, United States Active
Researchers
- Principal investigator: Tita, Alan Thevenet N. — University of Alabama at Birmingham
- Study coordinator: Tita, Alan Thevenet N.
Related research
Other NIH-funded projects on the same topics.
-
Global bromocriptine trial for postpartum cardiomyopathy
A large international study will test whether adding bromocriptine to standard heart failure treatment helps new mothers with peripartum cardiomyopathy.
-
Global Bromocriptine Add-on for Postpartum Heart Failure (GLOBal PPCM)
A large international study will test whether adding the dopamine agonist bromocriptine to standard heart failure care helps postpartum women with a specific heart condition.
-
Global Bromocriptine Trial for Postpartum Heart Failure (GLOBal PPCM)
A large international study will test whether adding bromocriptine to standard heart-failure care helps women with postpartum cardiomyopathy.
-
Bromocriptine as add-on therapy for postpartum cardiomyopathy across multiple sites
A large international study will test whether adding bromocriptine to standard heart failure treatment helps new mothers with postpartum cardiomyopathy.
-
Global bromocriptine trial to help postpartum heart failure patients
A large international trial tests whether adding bromocriptine to standard heart failure treatment improves outcomes for new mothers with a specific pregnancy-related heart condition.
-
Global Bromocriptine Trial to Help Postpartum Heart Failure
A large international study will test whether adding bromocriptine to standard heart failure treatment helps women with postpartum cardiomyopathy.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.